![Schematic representation of ERR structures and DNA binding mode.\
A) Schematic structure of the various ERR isoforms. Like most nuclear receptors, the ERRs possess three core domains, a regulatory amino-terminal domain (NTD), a DNA binding domain (DBD) and a ligand binding domain (LBD), in which the activation function 2 (AF-2, white box) is embedded at its carboxy terminal end. The AF-2 is required for ERR interaction with the coactivator PGC-1 and corepressor RIP140. B) Consensus ERR response element, as defined by motif-finding algorithms of ERR target gene promoters (Dufour et al., 2007). C) ERRs can bind to the ERRE as monomers, homodimers and heterodimers.](nrs05009.f1){#fig1}

![Central role played by ERRα and ERRγ in the control of energy metabolism.\
Induction of the expression of the coactivator PGC-1α upon diverse physiological stimuli leads to an augmentation in ERR transcriptional activity, as well as an increase in ERRα levels through an autoregulatory mechanism. The ERRs then upregulate the expression of other transcription factors, such as PPARα and GABPA, thus amplifying the original signal. These factors, working in concert with PGC1α and PGC-β, stimulate the expression of a vast genetic program controlling mitochondrial biogenesis, OXPHOS and ROS production. ERRα also stimulates the expression of RIP140, which provides an inhibitory feedback mechanism. Mitochondrial output is then used in a tissue-specific manner to modulate diverse biological responses.](nrs05009.f2){#fig2}

###### List of known ERR functions and associated target genes.

The table shows a list of physiological and developmental functions regulated by the three ERR isoforms in diverse tissues. Prototypic ERR target genes for each tissue are also listed. References to ERR functions and target genes can be found in the main text.
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Introduction
============

The nuclear receptor (NR) superfamily was originally defined as a group of structurally-related transcription factors controlling gene expression in response to binding to small lipophilic ligands best represented by the steroid and thyroid hormones, as well as vitamin D and the active derivatives of vitamin A \[[@r35]\]. However, it was soon realized that the number of nuclear receptors exceeded the number of known, classic lipophilic hormones, and receptors that could not be matched with a natural ligand were labeled as orphan nuclear receptors \[[@r40]; [@r42]\]. The emerging challenge was to perform "reverse endocrinology", starting with a gene encoding a putative receptor and ending up with a corresponding natural ligand and/or the recognition of the developmental and physiological processes modulated by these receptor-like proteins \[[@r60]\]. Here, we will review the current knowledge on the NR3B subgroup of nuclear receptors, commonly known as estrogen-related receptors (ERRs), the first orphan nuclear receptors identified, and still in search of a natural ligand.

The NR3B family
===============

Multiple ERR isoforms
---------------------

The NR3B subgroup includes three nuclear receptors referred to as ERRα (NR3B1, ERR1, *ESRRA*), ERRβ (NR3B2, ERR2, *ESRRB*) and ERRγ (NR3B3, ERR3, *ESRRG*), respectively. Members of the NR3B subgroup belong to the larger NR3 class of nuclear receptors that includes the classic steroid hormone receptors for estrogens, androgens, progesterone, aldosterone and cortisol. The first member of the subgroup (ERRα) was originally identified owing to the significant nucleotide and primary amino acid sequence similarities that it shared with the estrogen receptor α (NR2B1) gene and protein, while ERRβ was identified using the ERRα cDNA as a probe \[[@r42]\]. Ironically, while ERRα was the first orphan nuclear receptor identified, ERRγ was the final addition to the superfamily \[[@r34]; [@r45]; [@r48]\]. Although ERR homologs also exist in invertebrates such as *Drosophila* \[[@r90]\] and amphioxus (*Branchiostoma floridae*) \[[@r7]\], suggesting an ancient origin for the ERRs, it is not yet possible to identify the ancestral member of the NR3 group \[[@r6]\]. The genomic organization of the three ERR loci also shares a structural characteristic unique among receptor isoforms within a subgroup of the superfamily. The exon encoding the amino terminal domain of the receptor also encodes the first zinc finger of the DNA binding domain, a genetic link between the two domains that could explain the unusual level of amino acid sequence identity present in the amino terminal domains of the three ERR isoforms. A single polypeptide of 423 amino acid residues encodes human ERRα, while several splice variants of ERRβ and γ have been identified in human ([Figure 1](#fig1){ref-type="fig"}A). The ERRβ2 variant contains an extended carboxy-terminal domain \[[@r27]\], ERRβ2Δ10 lacks exon 10 and encodes a different carboxy-terminal region \[[@r121]\], the ERRγ2 splice variant possesses an additional 23 amino acids within its amino-terminal domain \[[@r45]; [@r94]\], while a new ERRγ splice variant lacking 39 amino acid residues of the second zinc finger of the DNA-binding domain has been found to be expressed in adipocytes and the prostate \[[@r61]\]. The existence and relative abundance of most of these isoforms need to be confirmed by endogenous protein detection assays, while further studies are required to elucidate their putative physiological roles.

Expression of the ERR isoforms
------------------------------

In general, the ERRs display a similar tissue distribution in both mice and humans. The ERR isoforms are ubiquitously expressed. However, ERRα is generally more abundantly expressed than ERRγ, which in turn is more abundant than ERRβ. The three isoforms are expressed at elevated levels in tissues subjected to high energy demand, such as the heart and kidneys. ERRα is also expressed at high levels in the intestine, brown adipose tissue and skeletal muscles, while ERRγ mRNA can be found in abundance in the brain stem and the spinal cord. ERRβ can be found at relatively high levels in a subset of extra-embryonic ectoderm in the developing placenta and undifferentiated trophoblast stem cell lines, as well as in the adult eyes, inner ear, heart and kidneys \[[@r17]; [@r28]; [@r42]; [@r69]; [@r77]; [@r98]\]. The graphical views of the tissue-specific mRNA expression patterns for the three mouse ERR isoforms are available at \[[@r124]\].

Interestingly, it was shown that the expression of all three ERR isoforms displays distinct diurnal rhythmicity in tissues such as the liver, white adipose, skeletal muscle, uterus and bone \[[@r49]; [@r114]\], suggesting that the ERRs may serve as a molecular link between the circadian oscillator and energy metabolism (see below). In addition, physiological stress signals such as exposure to cold, exercise or fasting also induce ERRα expression in brown fat, skeletal muscles and liver, respectively \[[@r22]; [@r54]; [@r83]\]. It has also been shown that ERRα expression in bone marrow-derived macrophages is activated by lipopolysaccharide, interferon γ (IFN-γ) and interleukin 4 \[[@r8]; [@r87]\]. In addition, a 2-fold increase of ERRα mRNA expression has been demonstrated during differentiation of human bone marrow-derived mesodermal progenitor cells into osteoblasts \[[@r78]\].

Little is known about how the expression of the three ERR genes is controlled. The main regulator of ERRα expression has been shown to be the ERRs themselves \[[@r64]; [@r67]; [@r72]\]. The *ESRRA* promoter contains a polymorphic 23 base pair sequence (*ESRRA23*) that is present in 1-4 copies in human. Each *ESRRA23* element contains one perfect ERRE, as well as an additional nuclear receptor half-site. Transient transfection experiments have demonstrated that induction of the *ESRRA* promoter by PGC-1α is dependent on the presence of the *ESRRA23* element, and that the strength of the activation correlates with its dosage \[[@r64]\].

Transcriptional activity of the ERRs
====================================

Interactions with coregulatory proteins
---------------------------------------

The three ERRs are constitutively active transcription factors. Their transactivation properties are independent of any exogenously added natural ligand and their relative potency as transcriptional activators varies in cell context- and promoter-dependent manners. The three ERR isoforms bind to a number of coregulator proteins, which they also share with other NRs. Their transcriptional activity is increased by members of the steroid receptor coactivator (SRC) family (SRC-1, TIF-2/SRC-2, AIB1/ACTR/SRC-3) \[[@r48]; [@r110]; [@r118]\], the peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1) α and β \[[@r52]; [@r59]; [@r64]; [@r83]; [@r87]\], as well as the proline-rich nuclear receptor coregulatory protein (PNRC), PNRC2 and transducin-like enhancer of split 1 \[[@r46]; [@r119]; [@r120]\]. The transcriptional activity of the ERRs is also modulated by the nuclear receptor corepressor RIP140/Nrip1 \[[@r5]; [@r23]; [@r32]; [@r81]\]. The ERRs can interact with the orphan nuclear receptor small heterodimer partner (SHP; NR0B2), which represses their transcriptional activity \[[@r80]\]. SHP lacks a conventional DNA binding domain and interacts with several other members of the nuclear receptor superfamily to inhibit their receptor transcriptional activity. It is interesting to note that the mutations in SHP that have been associated with moderate obesity in humans prevent the inhibition of ERRγ activity \[[@r80]\].

ERR activity can be modulated by synthetic ligands
--------------------------------------------------

Despite the absence of response to natural estrogens, it has been reported that the transcriptional activity of all ERR isoforms is inhibited by the synthetic estrogen analog diethylstilbestrol (DES) \[[@r31]; [@r98]\]. The constitutive transcriptional activity of ERRβ and ERRγ, but not ERRα, can also be repressed by the selective estrogen receptor modulator (SERM) 4-hydroxytamoxifen (OHT), which behaves like a selective inverse agonist, causing the dissociation of coactivator protein \[[@r31]; [@r97]\]. Recently, bisphenol A, a ubiquitous environmental contaminant with estrogenic activity, was shown to bind to ERRγ and antagonize the repression of ERRγ activity induced by OHT \[[@r96]\]. Also, toxaphene and chlordane, two organochlorine pesticides with estrogen-like activity, have been identified as weak antagonists for ERRα \[[@r111]\]. However, mutation of phenylalanine 329, an amino acid crucial for the constitutive activity of the receptor, to an alanine residue, allowed toxaphene to act as an ERRα agonist instead \[[@r29]\]. In addition, the isoflavones genistein, daidzein, and biochanin A and the flavone 6,3\',4\'-trihydroxyflavone were identified as agonists of the ERRs by mammalian two-hybrid experiments under comparable conditions to those for the activation of ERα and ERβ \[[@r89]\]. It should be noted that binding of the organochlorine pesticide molecules to ERRα could not be directly demonstrated \[[@r98]\] and that structure-based predictions showed that flavone and isoflavone cannot be accommodated within the ERR binding pocket \[[@r44]\]. Although these compounds constitute useful tools to study the regulation of the ERRs, they share the pitfall of being non-specific to the ERRs, as they modulate the activity of other nuclear receptors such as the ERs. However, several synthetic compounds have recently been characterized as ERR-specific ligands. XCT790 is a highly specific inverse agonist for ERRα that disrupts the interaction between ERRα and PGC-1α and has no effect on either the ERs or the other ERR isoforms \[[@r18]; [@r109]\], while GSK5182, a tamoxifen analog, showed improved inverse agonist selectivity for ERRγ \[[@r25]\]. On the other hand, the structurally-related phenolic acyl hydrazones GSK4716 and DY131 were reported to effectively and selectively activate ERRβ and ERRγ \[[@r115]; [@r122]\].

The possible existence of a natural ligand for the ERRs remains an unresolved question. The initial crystal structure of unliganded ERRγ showed that the ligand-binding pocket is very small, approximately 280 Å \[[@r44]\]. Likewise, the unoccupied volume of the ligand-binding pocket of the unliganded ERRα bound to a PGC-1α coactivator peptide was reported to be \~100 Å \[[@r57]\], suggesting that a natural agonist would have to be composed of at most four to five non-hydrogen atoms. However, the crystal structures of the GSK4716 agonist-bound ERRγ and of the cyclohexylmethyl-(1-*p*-tolyl-1*H*-indol-3-ylmethyl)-amine inverse agonist-bound ERRα revealed that these ligands can force the rearrangement of amino acid residues in the respective ligand binding domains that allows access of the ligands to a larger ligand-binding pocket. The results of these experiments thus suggest that the plasticity of the ERR ligand binding pockets could allow for larger compounds to act as natural ligands \[[@r56]; [@r105]\]. The crystal structures of ERRα and ERRγ ligand-binding domains also provided strong evidence for ligand-independent transactivation by these receptors. In both cases, the apo-receptors are in a permanent active configuration and thus ready to interact with coregulatory proteins \[[@r44]; [@r56]; [@r57]; [@r105]\]. Because binding of the agonist GSK4617 does not affect the orientation of the AF-2 helix, the mechanism by which GSK4617 activates ERRγ is currently unknown. In contrast, binding of DES and 4-OHT to ERRγ induces the displacement of the AF-2 helix to a position that interferes with the recruitment of coactivators \[[@r43]; [@r105]\].

ERR target genes
================

Identification of the binding site
----------------------------------

The physiological roles played by nuclear receptors can often be ascribed by investigating their target genes. Unbiased binding site selection and characterization of the first ERR-responsive genes defined the ERR response element (ERRE) as the consensus nucleotide sequence TCAAGGTCA \[[@r55]; [@r85]; [@r103]\]. Bioinformatic analysis of a large set of ERR target promoters identified using a combination of chromatin immunoprecipitation (ChIP) and genomic DNA arrays (ChIP-on-chip) confirmed that the TCAAGGTCA motif serves as the main ERR binding site *in vivo* ([Figure 1](#fig1){ref-type="fig"}B) \[[@r33]\]. Although the consensus ERRE contains a single nuclear receptor core binding half-site, the ERRs can bind DNA either as monomers, homodimers or heterodimers ([Figure 1](#fig1){ref-type="fig"}C) \[[@r10]; [@r33]; [@r39]; [@r50]; [@r55]; [@r85]; [@r99]\]. ERRα and ERRβ have also been shown to bind the estrogen response element (ERE) as homodimers \[[@r102]; [@r113]; [@r118]\], and two studies even suggested that ERα and ERRα could heterodimerize *in vitro* \[[@r55]; [@r113]\]. However, convincing evidence that the ERRs can commonly bind to EREs and/or interact in a physiologically significant manner with the ERs *in vivo* is still lacking. A study of the *TFF1* (pS2) gene showed that while the promoter contains both an ERE and an ERRE, regulation by the ERRs is lost only when the ERRE is ablated, suggesting that the ERRE is the ERRs' legitimate binding site, at least on this promoter \[[@r68]\].

ERR target promoters
--------------------

Biochemical purification of HeLa cell nuclear extract proteins that bind to the Simian Virus 40 (SV40) late promoter first identified ERRα as a repressor of the transcription of the SV40 late genes \[[@r108]; [@r123]\]. In contrast, the ERRs have been shown to mainly activate the expression of cellular genes. Until recently, most ERR target genes had been identified through the discovery of a putative ERRE in the promoters of genes of interest. These included genes encoding the medium-chain acyl coenzyme A dehydrogenase (MCAD or *Acadm*) \[[@r85]; [@r103]\], osteopontin (OPN) \[[@r15]; [@r101]\], the thyroid receptor α (TRα) \[[@r100]\], aromatase \[[@r112]\], lactoferrin \[[@r113]\], the orphan nuclear receptor SHP \[[@r80]\], endothelial nitric oxide synthase (eNOS) \[[@r91]\], PPARα \[[@r53]\], pyruvate dehydrogenase kinase 4 (PDK4) \[[@r2]; [@r107]; [@r116]\], monoamine oxidase B (MAO-B) \[[@r109]; [@r117]\], ERRα itself \[[@r64]; [@r67]; [@r72]\], apolipoprotein A4 (ApoA4) \[[@r19]\], phosphoenolpyruvate carboxykinase (PEPCK) \[[@r47]\], surfactant protein A (SP-A) \[[@r66]\], RIP-140/Nrip1 \[[@r73]\], mitofusin 2 \[[@r88]\], Polo-like kinase 2 (Plk2) \[[@r75]\] and uncoupling protein 1 (UCP-1) \[[@r32]\]. A second, more global approach to identifying ERR-responsive genes was to exploit the observation that ERRα transcriptional activity is highly stimulated in the presence of PGC-1α. Various cell lines were first infected with an adenovirus expressing either wild-type PGC-1α or a PGC-1α variant engineered to specifically interact with ERRα, and differential gene expression profiling was then carried out using DNA microarrays \[[@r37]; [@r72]; [@r79]; [@r82]\]. A small subset of *bona fide* ERRα targets were further identified using a combination of computational biology, small inhibitory RNAs (siRNAs) against ERRα, a specific antagonist, as well as DNA binding assays and cotransfection of reporter genes. These targets included several genes involved in oxidative phosphorylation (OXPHOS) and mitochondrial biogenesis, such as ATP synthase b (ATPsynb), cytochrome c (CYCS), COX4, GABPA, adenine nucleotide translocator 1 (ANT1) and carnitine palmytoyltransferase 1A (CPT1A), thus suggesting that ERRα could serve as a conduit for PGC-1α action in mitochondrial biogenesis and the OXPHOS pathway.

A powerful approach to identify direct target genes of nuclear receptors is to determine their occupancy on a genome-wide scale by using the ChIP-on-chip technology \[[@r20]; [@r21]; [@r63]; [@r74]\]. This technique was recently used to appraise the role of ERRα and ERRγ in the adult heart \[[@r33]\], of ERRγ in the newborn heart \[[@r1]\] and of ERRα in bone marrow-derived macrophages \[[@r87]\]. Together, these studies identified more than 500 promoters that considerably expanded the repertoire of direct ERR target genes encoding cytosolic and mitochondrial proteins involved in the control of energy metabolism. In addition, these studies showed that the ERRs control tissue-specific functions, such as fuel sensing and contractile work in the heart and bacterial clearance in macrophages. Further analyses of the ChIP-on-chip data demonstrated that ERRα and ERRγ target the same promoter as non-obligatory heterodimers and cooperate with other transcription factors, namely CREB and STAT3, to control of the expression of metabolic genes \[[@r33]\].

Regulatory networks
-------------------

Review of the data gathered on ERR coregulatory proteins and target genes described above also reveals an important emerging concept of ERRs functioning in a regulatory network. First, induction of PGC-1α expression by physiological stimuli leads to the upregulation of ERRα, which in turn stimulates its own expression, thereby generating a positive feedback loop \[[@r64]; [@r72]\]. Second, ERRα can also stimulate the expression of the corepressor RIP140 and SHP, thereby providing an inhibitory feedback mechanism to control the expression of its target genes \[[@r73]; [@r80]\]. Third, since the three ERR isoforms can regulate the same target genes as homo- or heterodimers, the expression of these genes can be differentially regulated depending on the levels of individual ERR isoform in each tissue. The existence of such networks has been shown *in vivo* where, in the ERRα null heart, the expression of RIP140 is downregulated, while that of PGC-1α is upregulated at a time when the expression of ERRγ is also elevated \[[@r33]\]. The compensatory mechanism was particularly evident in HL-1 cardiomyocytes, where ERRγ was shown to play an important role in maintaining the expression of ERRα target genes. A similar compensatory mechanism was observed in the neonatal heart lacking ERRγ \[[@r1]\].

Phenotypic analyses of ERR null mice
====================================

ERRα null mice: metabolic defects have tissue-specific consequences
-------------------------------------------------------------------

Initial phenotypic analysis of the ERRα null mice showed them to be viable and fertile with no gross anatomical alterations, with the exception of reduced body weight and peripheral fat deposits \[[@r70]\]. The ERRα null mice also showed altered expression of genes involved in lipid metabolism and OXPHOS in several tissues, including white adipose tissue, muscle and small intestine \[[@r19]; [@r53]; [@r70]\]. Although the changes observed in the expression of metabolic genes in these tissues should, in theory, lead the mice to burn less fat and spend less energy, the mice are paradoxically lean and resistant to high fat diet-induced obesity \[[@r70]\]. However, it was observed that, in the white adipose tissue of ERRα null mice, genes involved in fat catabolism were upregulated, while genes involved in triglyceride synthesis were downregulated. These data suggest that the ERRs can potentially function as both repressor and activator of gene expression in a tissue- and gene-specific manner. Together, these observations imply a more complex and tissue-specific role for ERRα in the control of energy metabolism in the whole animal. Indeed, subsequent investigation of the ERRα null mice showed that enterocytes from the null mice displayed a lower capacity for β-oxidation, and that ERRα-deficient pups exhibited a significant lipid malabsorption and fat transport \[[@r19]\]. In addition, ERRα null mice display a reduced mitochondrial mass in brown adipose tissue and impaired thermogenic capacity in response to cold temperatures, leading to hypothermia and slower recovery to a normal body temperature \[[@r104]\]. ERRα is thus essential for the organism in situations of high energy demand and defects in ERRα function could contribute to pathological states caused by mitochondrial dysfunction.

Given the observation that ERRα orchestrates a comprehensive transcriptional program in the heart \[[@r33]\] and the known link between metabolic disturbance and pathologic cardiac hypertrophy, ERRα null mice were recently tested for their response to stressors known to cause heart failure. Hearts of ERRα null mice subjected to pressure overload displayed chamber dilatation, reduced left ventricular shortening, depletion of the phosphocreatine pool and reduced ATP synthesis \[[@r51]\], indicating that ERRα is essential for the bioenergetic and functional adaptation to cardiac hemodynamic stressors.

Finally, recent studies of ERRα null macrophages showed that ERRα is required for the induction of mitochondrial reactive oxygen species (ROS) production and efficient clearance of pathogens in response to IFN-γ \[[@r87]\]. Consequently, the mitochondrial metabolic defect renders the ERRα null mice susceptible to infection by *Listeria monocytogenes*. The activation of ERRα by IFN-γ was also found to be dependent on the presence of the coactivator PGC-1β.

ERRβ: control of cell fate
--------------------------

Expression of ERRβ during early embryogenesis defines a subset of extra-embryonic ectoderm predestined to form the dome of the chorion \[[@r69]; [@r77]\]. Phenotypic analysis of the ERRβ null mice indeed showed abnormal chorion development associated with an overabundance of trophoblast giant cells and a severe deficiency of diploid trophoblasts \[[@r69]\]. Consequently, the ERRβ null mice die *in utero* at 10.5 days post-coitum due to impaired placental formation. Strikingly, treatment of trophoblast stem cells with DES, a synthetic estrogen that promotes coactivator release from ERRβ and inhibits its transcriptional activity, led to their differentiation toward the polyploid giant cell lineage \[[@r98]\]. In addition, DES-treated pregnant mice exhibited abnormal early placenta development associated with an overabundance of trophoblast giant cells and an absence of diploid trophoblast. These studies thus provided evidence for steroid-like control of trophoblast development.

Although essential for placental formation, tetraploid rescue experiments, as well as tissue-specific ablation of *Esrrb*, demonstrated that the ERRβ null embryos can develop normally and generate fertile adult animals of both sexes \[[@r28]; [@r69]; [@r71]\]. However, the ERRβ null mice of both sexes were found to have a reduced number of primordial germ cells in their gonads \[[@r71]\]. In addition, ERRβ null mice display abnormal development of the endolymph-producing cells of the inner ear, suggesting that potential ERRβ ligands could be used to treat some disorders of hearing and balance \[[@r28]\]. Taken together, these phenotypes advocate a more precise role for ERRβ than the other two ERR isoforms in the control of the fate of specific cell types during development.

ERRγ is required for the transition to oxidative metabolism in the postnatal heart
----------------------------------------------------------------------------------

ERRγ is expressed at high levels in the fetal and postnatal heart. ERRγ null mice display a reduction in ventricular mass and die shortly after birth \[[@r1]\]. Loss of ERRγ blocks the transition from a predominant dependence on carbohydrates as substrates during the fetal period to greater dependence on oxidative metabolism in postnatal life. The impairment in this switch resulted in lactatemia, electrocardiogram abnormalities, high mitochondrial genome number and altered electron transport chain biochemical activities \[[@r1]\]. Since pathologic conditions such as heart failure and cardiac hypertrophy can re-induce carbohydrate utilization, these findings suggest that like ERRα, ERRγ could be targeted for the management and/or treatment of cardiomyopathies.

ERRs and human diseases
=======================

Cancer
------

Evidence is accumulating towards a potential implication of the ERRs in the etiology of various types of cancer. The expression of all three ERR isoforms has been monitored in cancer cell lines or primary tumors derived from breast \[[@r3]; [@r68]; [@r95]; [@r121]\], ovary \[[@r92]\], prostate \[[@r30]; [@r36]\], endometrium \[[@r38]; [@r93]; [@r106]\] and colon \[[@r24]\]. In particular, ERRα has been identified as a bad prognosis indicator owing to its correlation with unfavorable biomarkers such as ERα negativity and elevated ErbB2 expression. On the other hand, ERRγ was associated with more favorable biomarkers such as hormone responsiveness in estrogen/progesterone receptor-positive tumors and expression of ErbB4, and its presence is therefore considered as a better prognosis indicator. Increased ERRα levels have also been associated with a higher risk of recurrence and poor clinical outcome in human breast carcinoma \[[@r3]; [@r95]\]. At the molecular level, it has been demonstrated that ERRα is phosphorylated in response to EGF signaling in MCF-7 breast cancer cells, a posttranslational modification that was linked to selective gene activation by ERRα \[[@r9]\]. Likewise, ERRα phosphorylation status and transcriptional activity were shown to be higher in a breast cancer cell line expressing high levels of ErbB2, while inhibition of ErbB2 signaling abrogated ERRα-induced transcription in these cells \[[@r4]\]. Lastly, coordinated upregulation of ERRα and its coactivators, PGC-1α and PGC-1β, as well as genes involved in glycolysis, tricarboxylic acid cycle and the OXPHOS pathway was observed in a human breast cancer model for brain metastasis \[[@r26]\]. These findings suggest that ERRα may direct a transcriptional switch that supports expression of oxidative metabolic pathways in metastatic cancer cells in the brain.

Osteoporosis, bone maintenance and cartilage formation
------------------------------------------------------

Given the structural and functional similarities between the ERRs and ERs, and the important role that estrogens play in bone formation and maintenance, a potential role for ERRα in bone physiology is under investigation \[[@r12]; [@r41]\]. ERRα is expressed in bone cells \[[@r11]; [@r13]; [@r14]; [@r15]; [@r85]\] and directly regulates osteoblast-associated genes such as OPN \[[@r101]\], lactoferrin \[[@r113]\], TRα \[[@r100]\], aromatase \[[@r112]\] and eNOS \[[@r91]\]. In addition, ERRα expression has been shown to be regulated by estradiol, both in cultured rat calvaria cells and *in vivo* \[[@r13]\]. However, it is currently unknown whether ERRα regulates estrogen-sensitive genes or interferes with estrogen signaling through indirect mechanisms. A statistically significant association between bone mass density (BMD) of white premenopausal women and *ESRRA23* was also observed in a genetic association study \[[@r62]\]. Women with more copies of ESRRA23 showed a higher BMD. The study concluded that lower copy number of ESRRA23 is associated with lower BMD and likely increased risk of bone fracture.

Expression of ERRα has also been reported in fetal and adult rat chondrocytes in growth plate and articular cartilage and in the rat chondrogenic cell line C5.18 \[[@r16]\]. Overexpression of ERRα in C5.18 cells induces the expression of the transcription factor SOX9, an important gene in cartilage formation. On the other hand, reduction of ERRα expression by a siRNA led to inhibition of cartilage formation and maturation of proliferating chondrocytes into hypertrophic chondrocytes *in vitro*.

Obesity
-------

As noted above, ERRα is expressed in tissues with a high capacity for β-oxidation, is a main conduit for PGC-1α and PGC-1β activity, and the ERRα null mice have reduced body weight and are resistant to high fat diet-induced obesity. In addition, *ESRRA* is located on chromosome 11q13 \[[@r84]; [@r86]\], a region previously linked to body mass index (BMI) and fat content \[[@r76]\]. Association studies between *ESRRA* variants located either in the promoter (*ESRRA23*, \[[@r64]\]) or in the coding region (Pro116Pro, \[[@r65]\]) with obesity and type 2 diabetes have so far given mixed results. While Kamei et al. \[[@r58]\] found that the 2.3 genotype of *ESRRA23* was associated with a higher BMI in Japanese individuals, Larsen et al. \[[@r65]\] found no association of the *ESRRA23* or Pro116Pro variants with obesity or type 2 diabetes in Danish whites.

Closing remarks
===============

While the ERRs remain orphan nuclear receptors as the search for a natural ligand continues, it has become clear that the three ERR isoforms are essential transcriptional regulators of development and physiology ([Table 1](#table-fn1){ref-type="table"}). Control of energy metabolism, through their interaction with members of the PGC-1 family of coactivator proteins, as well as with the corepressor RIP140, appears to be at the core of ERR biological activities ([Figure 2](#fig2){ref-type="fig"}). Given that the ERRs are proven druggable targets, it is hoped that the development of isoform-specific ERR agonists and antagonists will lead to new therapeutic approaches to manage and/or treat a variety of diseases that could include cardiomyopathies, osteoporosis, infection by pathogens, diabetes, obesity and cancer.
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